APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy

Ítems similars

• APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
  per: Viscusi ER, et al.
  Publicat: (2019-03-01)
• APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
  per: Singla, Neil K., et al.
  Publicat: (2019)
• A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
  per: Singla, Neil, et al.
  Publicat: (2017)
• Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
  per: Lambert, David, et al.
  Publicat: (2020)
• How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways
  per: Schneider, Sebastian, et al.
  Publicat: (2016)